The acceptance of HPN328 for a rapid oral presentation at a significant medical symposium is a positive development for Harpoon Therapeutics. It suggests that the treatment has potential and is of interest to the medical community, which could lead to increased investor confidence and a rise in stock price. However, the actual impact on the stock will depend on the details of the presentation and the market's perception of its significance.